Fig. 5

CDC20 remodels an immune-suppressive microenvironment through GSDME A The mRNA expression of CDC20 was compared between the CDC20 low and high groups in the prostate cancer patients from the TCGA-PRAD datasets. B Box plot analysis exhibiting distinct infiltration of immune cells subpopulation in prostate cancer at different CDC20 expression levels (CDC20_low and CDC20_high). C Box plots show the statistical comparison of the mRNA expression of marker genes in various immune cells at different CDC20 expression levels (CDC20_low and CDC20_high). D–E GSEA-based GO analysis-enrichment plots of representative gene sets, which activated D or suppressed E in prostate cancer patients with CDC20-high expression. The colored line means enrichment profile. F The schematic graph and the picture of xenografts after the sacrifice of BALB/c mice bearing TRAMP-C2 tumors. G The volume of xenografts in BALB/c mice bearing TRAMP-C2 tumors was measured every 3 days from the 7th day after implantation (5 mice per group). H The schematic graph and the picture of xenografts after the sacrifice of C57BL/6 mice bearing TRAMP-C2 tumors infected with the indicated lentiviral shRNA constructs. I The volume of xenografts in C57BL/6 mice bearing TRAMP-C2 tumors infected with the indicated lentiviral shRNA constructs was measured every 3 days from the  7 day after implantation (5 mice per group)